Cacabelos, RamónTorrellas, ClaraTeijido Hermida, ÓscarCarril, Juan Carlos2025-04-012025-04-012016Cacabelos, R., Torrellas, C., Teijido, O., Carril, J. C. (2016) Pharmacogenetic considerations in the treatment of Alzheimer's disease. Pharmacogenomics, 17(9), 1041-1074. https://doi.org/10.2217/pgs-2016-0031.1462-241610.2217/pgs-2016-0031https://academica-e.unavarra.es/handle/2454/53889Acceso cerrado a este documento. No se encuentra disponible para la consulta pública. Depositado en Academica-e para cumplir con los requisitos de evaluación y acreditación académica del autor/a (sexenios, acreditaciones, etc.).The practical pharmacogenetics of Alzheimer’s disease (AD) is circumscribed to acetylcholinesterase inhibitors (AChEIs) and memantine. However, pharmacogenetic procedures should be applied to novel strategies in AD therapeutics including: novel AChEIs and neurotransmitter regulators, anti-Aβ treatments, anti-tau treatments, pleiotropic products, epigenetic drugs and combination therapies. Genes involved in the pharmacogenetic network are under the influence of the epigenetic machinery which regulates gene expression transcriptionally and post-transcriptionally, configuring the fundamentals of pharmacoepigenomics. Over 60% of AD patients present concomitant pathologies demanding additional treatments which increase the likelihood of drug–drug interactions. Lipid metabolism dysfunction is a pathogenic mechanism inherent to AD neurodegeneration. The therapeutic response to hypolipidemic compounds is influenced by the APOE and CYP genotypes. The development of novel compounds and the use of combination/multifactorial treatments require the implantation of pharmacogenomic procedures for the avoidance of ADRs and the optimization of therapeutics.application/pdfeng© 2016 Future Medicine Ltd.Alzheimer's diseaseAntidementia drugsAPOECYPsDrug interactionsEpigeneticsLipid metabolism dysfunctionPharmacoepigenomicsPharmacogenomicsTransportersinfo:eu-repo/semantics/article2025-04-01info:eu-repo/semantics/closedAccess